NCT05741346 - Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 18, 2023

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2025

Conditions

Paroxysmal Nocturnal Hemoglobinuria

Interventions

DRUG

BCX9930

Taken orally at 400 mg twice daily (BID)

Trial Locations (11)

Investigative Site, Paris

Investigative Site, Budapest

Investigative Site, Ampang

Investigative Site, Bloemfontein

Investigative Site, Cape Town

Investigative Site, Pretoria

Investigative Site, Daejeon

Investigative Site, Barcelona

Investigative Site, Valencia

Investigative Site, Leeds

Investigative Site, London